Cargando…
Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
The main therapeutic strategy for metastatic Myxofibrosarcoma (MFS) is palliative chemotherapy. A number of studies have demonstrated that anti-angiogenic therapy and immunotherapy could improve the survival rate of patients with metastases. However, the effectiveness of the combination of anti-angi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468213/ https://www.ncbi.nlm.nih.gov/pubmed/32905214 http://dx.doi.org/10.3892/mco.2020.2124 |